Unfiltered Patient Insights: Commonalities and Differences in Living With Chronic Myeloid Leukemia and Multiple Myeloma

Fatima Scipione, 1,2 Kim Gibbs, 1 Christine Verini 3

¹Takeda Pharmaceuticals America, Inc., Lexington, MA, USA; ²International Myeloma Foundation, Studio City, CA, USA; ³CancerCare, New York, NY, USA.




Context

 Although many studies evaluating the therapeutic efficacy of investigational cancer drugs exist, few studies have used insights directly from patients to focus on the holistic experiences of people with cancer

Objective


• To understand the multifactorial experiences of people with chronic myeloid leukemia (CML) and multiple myeloma (MM), with a focus on the behavioral, psychosocial, cognitive, linguistic, and interactional domains of patient experiences (Figure 1) and to use this patient-centric approach to improve care

Figure 1: Behavioral, psychosocial, cognitive, linguistic, and interactional domains of patient experiences captured in patient surveys and interviews.









The means to construct patient points of access and communication

The icons in this figure are shown in later figures to denote aspects of patient experiences that fall into each respective domain

Methods

 US patients with CML and MM and their care partners were interviewed (qualitative) analysis) or surveyed (quantitative survey) between June 2020 and March 2021 after responding affirmatively to a request to be interviewed or surveyed

Conclusions

- Differences in treatment paradigms, sites of care, expectation management, and the availability of novel therapies and patient support groups resulted in drastically different experiences for patients with CML and MM across the behavioral, psychosocial, cognitive, linguistic, and interactional domains
- Patients with CML frequently felt isolated and disillusioned, while those with MM felt optimistic and supported
- Upfront education, in lay terms, regarding disease prognosis and severity, treatment side effects, and potential medication switches may improve patient experiences, particularly for those with CML
- Patient advocacy is a vital resource for both physicians and patients; greater and earlier access to reputable patient advocacy groups is desperately needed to support patients with CML
- Examples of reputable patient advocacy groups include CancerCare, the International Myeloma Foundation, and the Leukemia & Lymphoma Society

Results the quantitative survey population included 25 patients with CML and 9 care partners of patients with CML Figure 4: Patients with MM were more confident in the information available to them than patients with CML. In the survey, patients were asked, "How confident are Figure 3: Patient experiences differed due to the availability you that you have all the information you need to understand and make of new and effective treatments. decisions about the management and treatment for your CML or MM?" Figure 2: Patient experiences diverged rapidly post-diagnosis based on "I feel a great deal of optimism about the present Among those qualitatively and future management of my MM because of all interactions with HCPs. In the survey, patients were asked whether they primarily for the treatment of my CML." the new treatments being approved by the FDA interviewed were 15 patients received their care from a local oncologist, a CML or MM specialist, or both and in late-stage research trials." with MM and 10 care partners of patients with MM; the quantitative survey population included 33 patients with MM and 10 care partners of patients with MM CML (n = 25)MM (n = 33)Patients with MM (n = 33) Completely confident Somewhat confident Not confident at all Agree completely Somewhat agree Neutral ■ Somewhat disagree ■ Disagree completely FDA, US Food and Drug Administration. Patient experiences with advocacy/support groups and academic sites of care ■ Local oncologist ■ CML or MM specialist ■ Both Patient experiences with treatments and side effects Patients with CML noted that HCP recommendations to patient advocacy/support groups HCP, health care provider. Patients in both groups felt unprepared for treatment side effects and were lacking, prolonging feelings of isolation and hopelessness and leading patients to Patient experiences post-diagnosis and interactions with HCPs expressed a desire for more upfront preparation and education seek out alternative sources of information (Figure 4) All patients were shocked by their diagnosis and initially felt ill-prepared to participate Patients with CML sought out alternative sources of information Patients with MM, however, had greater and earlier access to both patient advocacy in discussions or decision making with their health care team (Figure 2) groups and academic sites of care with MM specialists, particularly for those who regarding side effect management; they experienced anxiety, concern of Patients with CML were frequently told by doctors that they had the "good cancer," relapse, and fear of running out of options with each medication switch (Figure 3) received stem cell transplants leading to frustration and disillusionment Patients with CML and MM were introduced to a complex new lexicon Among patients with MM surveyed, 76% listed online patient advocacy/support groups, Conversely, patients with MM felt optimistic due to the large pipeline of available 55% listed support groups, and 52% listed other individuals with MM as valuable sources of of terminology regarding their disease and treatments (eg, "T315I positive" treatment options and therapies under development for CML, "RVD" [Revlimid®, Velcade®, dexamethasone] for MM) information regarding their disease and treatment options Those with MM were able to adapt to a "new normal" of living with their disease and treatment side effects Specialist (MM) versus Lack of knowledge Local oncologists, family, and friends (CML) versus patient advocacy/support groups and academic sites of care (MM) Seeking alternative sources of information (CML) Isolation and Ioneliness (CML) versus patient advocacy group support and empowered decision making (MM) versus empowerment (MM) ack of education regarding New, complex terminology, eg, treatment side effects genetic mutations ("T315I positive") and Adapting to a "new normal"

Acknowledgments

Professional medical writing assistance was provided by William J. Kelley, PhD, and Matt McErlean, PhD, of Lumanity Communications Inc. (Yardley, PA, USA), and funded by Takeda Pharmaceuticals America, Inc. (Lexington, MA, USA).

Disclosures

This study was funded by Takeda Pharmaceuticals America, Inc. FS: former employment with Takeda Pharmaceuticals America, Inc.; current employment with the International Myeloma Foundation. KG: employment with Takeda Pharmaceuticals America, Inc. CV: employment with CancerCare.